QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
QQQ   270.75 (-0.11%)
TSLA   1,485.00 (+0.00%)
BA   173.30 (-0.56%)
Log in

NASDAQ:CHRSCoherus Biosciences Stock Price, Forecast & News

$18.17
+0.27 (+1.51 %)
(As of 08/6/2020 09:30 AM ET)
Add
Compare
Today's Range
$17.78
Now: $18.17
$18.32
50-Day Range
$16.69
MA: $17.88
$18.92
52-Week Range
$10.86
Now: $18.17
$23.91
Volume1.05 million shs
Average Volume872,034 shs
Market Capitalization$1.29 billion
P/E Ratio9.27
Dividend YieldN/A
Beta2.03
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More
Coherus Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$356.07 million
Cash Flow$1.35 per share
Book Value$1.50 per share

Profitability

Net Income$89.83 million

Miscellaneous

Employees232
Market Cap$1.29 billion
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$18.17
+0.27 (+1.51 %)
(As of 08/6/2020 09:30 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

How has Coherus Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CHRS stock has increased by 14.5% and is now trading at $18.17.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Coherus Biosciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Coherus Biosciences
.

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Coherus Biosciences
.

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.10. The biotechnology company earned $116.18 million during the quarter, compared to the consensus estimate of $116.25 million. Coherus Biosciences had a net margin of 33.42% and a return on equity of 190.82%.
View Coherus Biosciences' earnings history
.

What price target have analysts set for CHRS?

9 analysts have issued twelve-month price targets for Coherus Biosciences' stock. Their forecasts range from $20.00 to $43.00. On average, they anticipate Coherus Biosciences' share price to reach $29.78 in the next year. This suggests a possible upside of 63.9% from the stock's current price.
View analysts' price targets for Coherus Biosciences
.

Has Coherus Biosciences been receiving favorable news coverage?

News coverage about CHRS stock has been trending negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Coherus Biosciences earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Coherus Biosciences
.

Are investors shorting Coherus Biosciences?

Coherus Biosciences saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 18,290,000 shares, an increase of 18.6% from the June 15th total of 15,420,000 shares. Based on an average daily trading volume, of 1,780,000 shares, the days-to-cover ratio is currently 10.3 days. Approximately 28.2% of the shares of the company are short sold.
View Coherus Biosciences' Current Options Chain
.

Who are some of Coherus Biosciences' key competitors?

What other stocks do shareholders of Coherus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Exelixis (EXEL), Intelsat (I), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Pfizer (PFE).

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
  • Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
  • Dr. Peter K. Watler, Chief Technical Officer (Age 57)
  • Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
  • Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Redwood Investments LLC (1.26%), Candriam Luxembourg S.C.A. (0.94%), Principal Financial Group Inc. (0.75%), Peregrine Capital Management LLC (0.63%), Swiss National Bank (0.18%) and Cadence Capital Management LLC (0.16%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti.
View institutional ownership trends for Coherus Biosciences
.

Which major investors are selling Coherus Biosciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Alps Advisors Inc., Foundry Partners LLC, Russell Investments Group Ltd., Wakefield Asset Management LLLP, and Intrust Bank NA. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti.
View insider buying and selling activity for Coherus Biosciences
.

Which major investors are buying Coherus Biosciences stock?

CHRS stock was acquired by a variety of institutional investors in the last quarter, including Redwood Investments LLC, Principal Financial Group Inc., Candriam Luxembourg S.C.A., Comerica Bank, Ziegler Capital Management LLC, WINTON GROUP Ltd, Assenagon Asset Management S.A., and Texas Permanent School Fund.
View insider buying and selling activity for Coherus Biosciences
.

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $18.17.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $1.29 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.

What is Coherus Biosciences' official website?

The official website for Coherus Biosciences is www.coherus.com.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.